Human genetic defects of sphingolipid synthesis

13 May 2024 | Discover home page, Discover Melasphinx

Human genetic defects of sphingolipid synthesis Ceramide ; peripheral neuropathy Glycosphingolipid ; peripheral neuropathy; Ichthyosis ; neurodevelopment; Thierry Levade – Team Melasphinx – Ceramide metabolism in melanoma: from basic mechanisms to...

Study of the contribution of tumour lipids to the metastatic progression of cutaneous melanoma

22 Jan 2024 | Discover home page, Discover Melasphinx

Study of the contribution of tumour lipids to the metastatic progression of cutaneous melanoma E-cadherin, epidermis, melanoma,  metabolism, microenvironment, sphingosine 1-phosphate Joelle Riond and Nathalie Andrieu – équipe MELASPHINX – Ceramide...

Focus research 2022 MELASPHINX team

2 Oct 2023 | Discover Melasphinx

Focus research 2022 MELASPHINX team Discovery of new biomarkers of resistance to melanoma immunotherapies The team showed that neutralization of TNFα, a major inflammatory cytokine, potentiates the response to anti-PD-1 in murine models of melanoma. This work...

Towards a new approach to immunotherapy in the treatment of skin cancers

10 Dec 2022 | Discover home page, Discover Melasphinx, Discover RNAreg, Discover T2i

Towards a new approach to immunotherapy in the treatment of skin cancer – the ARC Foundation provides long-term support Over the past 10 years, immunotherapy has significantly improved the management of patients with metastatic melanoma, one of the rarest but...

Obesity and melanoma: a new link

23 Sep 2022 | Discover home page, Discover Melasphinx

Obesity and melanoma: a new link Melanoma p16INK4A Obesity CDKN2A Adipocytes beta-catenin extracellular vesicle Laurence Niéto – MELASPHINX Team – Métabolisme du céramide dans le mélanome : des mécanismes moléculaires à l’immunothérapie Obesity is a...

A new immunotherapy strategy for melanoma patients.

17 Dec 2021 | Discover home page, Discover Melasphinx

A new immunotherapy strategy for melanoma patients. Anti-TNF Anti-PD-1 Anti-CTLA-4 melanoma Clinical trial Bruno Ségui a Nicolas Meyer – Equipe “MELASPHINX : Sphingolipid metabolism: From basic mechanisms to immunotherapy Melanoma is a skin cancer with a poor...